Published in Eur J Clin Invest on April 01, 2002
Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med (2009) 1.24
The genetics of vascular complications in diabetes mellitus. Cardiol Clin (2010) 0.85
Probucol alleviates atherosclerosis and improves high density lipoprotein function. Lipids Health Dis (2011) 0.83
Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol Metab (2013) 0.82
Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.). Vasc Dis Prev (2009) 0.80
Paraoxonase and arylesterase activities, lipid profile, and oxidative damage in experimental ischemic colitis model. Gastroenterol Res Pract (2012) 0.80
Antioxidant properties of HDL. Front Pharmacol (2015) 0.78
Paraoxonase-1 gene Q192R and L55M polymorphisms and risk of cardiovascular disease in Egyptian patients with type 2 diabetes mellitus. J Diabetes Metab Disord (2014) 0.78
Time-dependent modulation of rat serum paraoxonase 1 activity by fasting. Pflugers Arch (2006) 0.76
Hepatopancreatic intoxication of lambda cyhalothrin insecticide on albino rats. Int J Clin Exp Med (2015) 0.75
Paraoxonase1 genetic polymorphisms in a mixed ancestry African population. Mediators Inflamm (2014) 0.75
HDL or not HDL, that is the question. Eur J Clin Invest (2002) 0.75
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med (2002) 3.22
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia (2003) 2.45
Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 2.34
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Prevention of macrovascular disease: absolute proof or absolute risk? Diabet Med (1995) 1.93
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) (2003) 1.72
Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia (2005) 1.64
Increased Langerhan cell density and corneal nerve damage in diabetic patients: role of immune mechanisms in human diabetic neuropathy. Cont Lens Anterior Eye (2010) 1.61
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest (1982) 1.53
Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev (2011) 1.50
HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis (1995) 1.48
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol (1996) 1.48
Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E. Diabet Med (1999) 1.46
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol (1995) 1.40
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant (2001) 1.40
For the good that it will do: issues confronting healthcare in the UK. J R Soc Med (1999) 1.39
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem (1986) 1.37
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis (1990) 1.32
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med (2011) 1.24
Public health medicine in transition. J R Soc Med (2001) 1.24
Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med (2003) 1.22
Risk of diabetes-related amputation in South Asians vs. Europeans in the UK. Diabet Med (2002) 1.21
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med (2008) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.18
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
Esterases: problems of identification and classification. Biochem Pharmacol (1983) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med (2002) 1.16
Human cholesterol metabolism and therapeutic molecules. Exp Physiol (2008) 1.15
Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med (2002) 1.14
Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia (2009) 1.13
Effect of pectin on serum lipids and lipoproteins, whole-gut transit-time, and stool weight. Lancet (1976) 1.12
Clinical value of apolipoprotein measurement. Ann Clin Biochem (1991) 1.10
How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol (2000) 1.08
Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem (1987) 1.08
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb (1991) 1.07
Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet (1986) 1.04
Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest (2000) 1.03
Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J Cell Mol Med (2005) 1.02
The Neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia (2008) 1.01
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis (2003) 1.01
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J (1986) 1.01
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet (1997) 1.00
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) (2000) 0.98
Frequency of citation and outcome of cholesterol lowering trials. BMJ (1992) 0.98
Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract (2003) 0.98
The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med (2002) 0.97
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract (1992) 0.97
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Partial purification and properties of sheep serum "A'-esterases. Biochem Pharmacol (1983) 0.95
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet (1999) 0.95
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med (1989) 0.94
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94